Compare WHG & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WHG | SGMO |
|---|---|---|
| Founded | 1983 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 173.6M | 141.2M |
| IPO Year | 2002 | 2000 |
| Metric | WHG | SGMO |
|---|---|---|
| Price | $16.84 | $0.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 6.4K | ★ 8.0M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.61% | N/A |
| EPS Growth | ★ 203.85 | 10.20 |
| EPS | ★ 0.79 | N/A |
| Revenue | ★ $97,762,000.00 | $36,567,000.00 |
| Revenue This Year | N/A | $107.15 |
| Revenue Next Year | N/A | $76.44 |
| P/E Ratio | $21.47 | ★ N/A |
| Revenue Growth | 3.21 | ★ 88.60 |
| 52 Week Low | $14.51 | $0.14 |
| 52 Week High | $18.99 | $0.79 |
| Indicator | WHG | SGMO |
|---|---|---|
| Relative Strength Index (RSI) | 60.37 | 31.59 |
| Support Level | $17.28 | N/A |
| Resistance Level | $18.68 | $0.55 |
| Average True Range (ATR) | 0.66 | 0.03 |
| MACD | 0.07 | -0.00 |
| Stochastic Oscillator | 100.00 | 36.11 |
Westwood Holdings Group Inc manages investment assets and provides services for clients through subsidiaries. It operates its business through the Advisory and Trust segments. Its advisory segment provides investment advisory services to corporate retirement plans, public retirement plans, endowments, foundations, individuals and the Westwood Funds, as well as investment sub-advisory services to mutual funds and its trust segment. The Trust segment offers trust and custodial services to its clients and its advisory segment sponsors common trust funds to institutions and high net-worth individuals. It generates maximum revenue from the Advisory segment. Geographically, it derives a majority of its revenue from the United States.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.